The primary endpoint of this study is to assess the objective tumor response rate in patients
with advanced epithelial ovarian cancer receiving combination of Gemcitabine at a dose 1250
mg/m2 (Day 1 and 8) with Cisplatin 75 mg/m2 (Day 1) as first-line treatment